일본 첫 임상 원격 로봇수술, 히로사키대 히노토리로 5건 시행

The first clinical telesurgery cases in Japan turn a decade of guideline work into a registered, reviewable study on patients. The precedent is procedural: any hospital pair that can meet the Japan Surgical Society's second-edition guideline, obtain certified review-board approval and register in jRCT now has a template. That lowers the barrier for regional hospitals far more than any network upgrade would.

It also ties the first patient data to a domestic platform. In a market where Intuitive's installed base sets the scale, being the robot named in the country's first clinical telesurgery is a differentiator Medicaroid can use with Japanese hospitals and in the four markets where hinotori is approved.

Intuitive (11,710 da Vinci systems installed on June 30, 2026, per its Q2 release) dominates installed base; MEKAWIRE has no verified record of a clinical da Vinci telesurgery in Japan, so the comparison is about firsts, not capability. MicroPort MedBot's Toumai has been used for long-distance and cross-border demonstrations, including Korea University Anam Hospital's Seoul to Shanghai animal-model case on Oct 16. Kyushu University's IOWN trial points to a parallel Japanese track focused on microsurgery and photonic networks.

The Hirosaki model is the most conservative of the three: regional distance, commercial line, local surgeon present. Its advantage is regulatory standing, not reach.

Medicaroid is a private joint venture of Kawasaki Heavy Industries and Sysmex and discloses neither revenue nor installed base, so no valuation comparison is possible. Its value to the parents shows up in approvals (Japan 2020, Singapore 2023, Malaysia 2024, Vietnam 2026, CE mark 2026) and in clinical firsts such as this one. Investors in Kawasaki and Sysmex should treat the news as a qualitative milestone without a disclosed financial effect.

The study uses a Japanese robot and a Japanese carrier's commercial WAN service. The network layer is an ordinary enterprise product, which means the binding constraints are clinical governance and staffing, not components. For component suppliers to surgical robots, a growing telesurgery use case raises the value of low-latency video, haptic and control electronics, but the release gives no technical data that would size that demand.

Results or updates filed under jRCTs022240038. Whether the Kyushu University IOWN trial, which runs through 2027, produces a university release with patient cases. Medicaroid's first remote use of hinotori outside Japan, now that it holds a CE mark. A decision by Japanese payers on recognising remote support during robotic surgery.

Thesis: the milestone is governance, not engineering, and it strengthens a domestic platform at home. Confidence: medium. The facts are primary and clear, but five cases and no published latency or intervention data leave the clinical value open. A data release showing frequent, meaningful remote interventions would raise confidence; a study that stalls at a handful of cases would lower it.

How often did the remote surgeon actually intervene in the five cases, and what latency did the link show? What is the fallback procedure if the link drops mid-operation? Will Medicaroid offer telesurgery support as a service with hinotori sales abroad? How many more hospital pairs are preparing under the same guideline?